ALLOPURINOL TABLETS 300MG 300 MG
ALLOPURINOL : 300 MG · DIN 02232613 · LABORATOIRES CONFAB INC
Health Canada status: CANCELLED PRE MARKET
What is ALLOPURINOL TABLETS 300MG?
ALLOPURINOL TABLETS 300MG 300 MG contains ALLOPURINOL : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02232613, held by LABORATOIRES CONFAB INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 09-Apr-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is ALLOPURINOL TABLETS 300MG called?
The same molecule, ALLOPURINOL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Zyloric | Latin | Bahrain, Morocco, Norway, Saudi Arabia |
| Allopurinol Sandoz | Latin | Australia, Norway, Sweden |
| MILURIT | Latin | Czechia |
| Zyloprim | Latin | Australia, South Africa |
| PURINOL | Latin | Czechia, Morocco |
| Allopurinol Nordic Drugs | Latin | Sweden |
| Allopurinol Orifarm | Latin | Sweden |
| Allopurinol Orion | Latin | Norway, Sweden |
| ALLOPURINOL-WGR | Latin | Australia |
| Allosig | Latin | Australia |
| APO-ALLOPURINOL | Latin | Australia |
| Progout Viatris | Latin | Australia |
| Puricos | Latin | South Africa |
| ALOPURINOL SANDOZ | Latin | Czechia |
| Redurate | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02232613 |
|---|---|
| Brand name | ALLOPURINOL TABLETS 300MG |
| Generic / active ingredient | ALLOPURINOL : 300 MG |
| Manufacturer | LABORATOIRES CONFAB INC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M04AA01 ALLOPURINOL |
| AHFS class | 92:16.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 09-Apr-2021 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02232613 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2232613 |
| Brand name | ALLOPURINOL TABLETS 300MG |
| Active ingredient / INN | ALLOPURINOL : 300 MG |
| ATC code | M04AA01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M04 |
| AHFS class | 92:16.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | LABORATOIRES CONFAB INC |
Which pack is which?
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code M04AA01 ALLOPURINOL. 12 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALLOPURINOL-100 | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00555681 |
| ALLOPURINOL-200 | 200 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02130157 |
| ALLOPURINOL-300 | 300 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00555703 |
| APO-ALLOPURINOL TABLETS | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00402818 |
| APO-ALLOPURINOL TABLETS | 200 MG | TABLET | APOTEX INC | MARKETED | DIN 00479799 |
| APO-ALLOPURINOL TABLETS | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 00402796 |
| JAMP ALLOPURINOL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421593 |
| JAMP ALLOPURINOL | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421607 |
| JAMP ALLOPURINOL | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421615 |
| MAR-ALLOPURINOL | 100 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02396327 |
Who else supplies ALLOPURINOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALLOPURINOL appears in 369 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does ALLOPURINOL cost around the world?
ALLOPURINOL is listed on 16 national price registers Nexara tracks, across 259 pack listings published on 14 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 3 | 83 | 03 Sep 2026 |
| Australia | ex-manufacturer | 9 | 30 | 08 Sep 2026 |
| South Africa | single exit price | 18 | 28 | 01 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 15 | 20 | 03 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 6 | 18 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 4 | 14 | 03 Sep 2026 |
| Saudi Arabia | public | 11 | 12 | 01 Sep 2026 |
| Morocco | PPV (public price) | 3 | 11 | 05 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 4 | 9 | 07 Sep 2026 |
| United Arab Emirates | public | 6 | 7 | 31 Aug 2026 |
| Bahrain | retail (max) | 4 | 7 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 7 | 7 | 03 Sep 2026 |
| Luxembourg | reimbursement | 6 | 6 | 05 Sep 2026 |
| Hungary | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
| Romania | max producer price | 1 | 1 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.